Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Neoplasms 8Neoplasms by Site 4Digestive System Neoplasms 4Pancreatic Neoplasms 3Neoplasms, Glandular and Epithelial 3Digestive System Diseases 3Colorectal Neoplasms 3Pancreatic Diseases 2Neoplasms by Histologic Type 2Endocrine Gland Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Thymus Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Neoplasms 1Rectal Diseases 1Previously Treated Metastatic Colorectal Cancer 1Pancreatic cancer, adult 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intestinal Neoplasms 1Intestinal Diseases 1

Interventions

pembrolizumab 3napabucasin 3Bevacizumab 3entinostat 2Paclitaxel 2Ocoxin 2Leucovorin 2Irinotecan 2Immunotherapy 2Gemcitabine 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vorasidenib 1sipuleucel-T 1pralsetinib 1palbociclib 1luprolide acetate gel depot 1linifanib 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1durvalumab 1catumaxomab 1Vaccines 1VB6-845 fusion protein 1Taxes 1Sorafenib 1Pemetrexed 1Papillomavirus Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Glandular and Epithelial × napabucasin × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡